R&D In Brief: Amgen, Arrowhead, Rigel, Coherus, Achillion
Executive Summary
Arrowhead readies to advance its RNAi candidate for hepatitis B, while data on Achillion’s ‘3102 plus Sovaldi prepare the firm to start trials of its proprietary HCV combo. Coherus advances with a Humira biosimilar and Amgen will file Kyprolis for new indication despite failed study, while Rigel dry-eye failure has the firm refocusing on fostamatinib.
You may also be interested in...
Onyx Provides Detail On Frontline Strategy For Kyprolis
Onyx supplied details about its clinical plans to enable frontline approval for Kyprolis to treat multiple myeloma and to effectively compete against well-established proteasome inhibitor competitor Velcade. It also elaborated further on its pipeline plans and deal-making strategy at an analyst day on March 14.
Rigel’s High Science Bet
In an era in which biotechs focus on specialty drugs in niche populations, Rigel has been building a portfolio that looks different from other biopharmas in terms of what goes in and how it goes out. Although the company is currently valued on the performance of fostamatinib, investors might do well to take notice of Rigel’s pipeline.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.